{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:56:33Z","timestamp":1792803393919,"version":"4.5.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.dld.2024.01.208","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T19:23:05Z","timestamp":1708456985000},"page":"756-769","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"Thierry","family":"Lecomte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Chautard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bressand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Lagasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Come","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lucidarme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Martin-Babau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Panis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Portales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2024.01.208_bib0001","unstructured":"Colon non m\u00e9tastatique. https:\/\/www.snfge.org\/content\/3-cancer-du-colon-non-metastatique."},{"key":"10.1016\/j.dld.2024.01.208_bib0002","series-title":"TNM classification of malignant tumours","year":"2017"},{"key":"10.1016\/j.dld.2024.01.208_bib0003","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2003.05.062","article-title":"Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup Trial INT-0089","volume":"21","author":"Le Voyer","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0004","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.01.208_bib0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/gutjnl-2012-304356","article-title":"Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts","volume":"62","author":"Vasen","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.01.208_bib0006","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.dld.2012.09.013","article-title":"Deficient mis-match repair phenotype is a prognostic factor for colorectal cancer in elderly patients","volume":"45","author":"Aparicio","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.01.208_bib0007","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0008","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/path.1851","article-title":"Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified","volume":"207","author":"Ward","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.dld.2024.01.208_bib0010","unstructured":"Patients atteints d'un ad\u00e9nocarcinome colorectal \/Indications des tests mol\u00e9culaires en vue de la prescription de traitements de pr\u00e9cision, collection Recommandations et r\u00e9f\u00e9rentiels, Institut national du cancer, juin 2022. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Patients-atteints-d-un-adenocarcinome-colorectal-Indications-des-tests-moleculaires-en-vue-de-la-prescription-de-traitements-de-precision."},{"key":"10.1016\/j.dld.2024.01.208_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2024.01.208_bib0012","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2214\/ajr.150.2.301","article-title":"Carcinoma of the colon: detection and preoperative staging by CT","volume":"150","author":"Balthazar","year":"1988","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.dld.2024.01.208_bib0013","first-page":"S275","article-title":"Conclusions et recommandations du jury. Texte de Consensus. Pr\u00e9vention, d\u00e9pistage et prise en charge des cancers du c\u00f4lon","volume":"22","year":"1998","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.dld.2024.01.208_bib0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/gutjnl-2019-319915","article-title":"Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)\/Association of Coloproctology of Great Britain and Ireland (ACPGBI)\/United Kingdom Cancer Genetics Group (UKCGG)","volume":"69","author":"Monahan","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.01.208_bib0015","unstructured":"\u00c9valuation du statut MMR tumoral, collection recommandations et r\u00e9f\u00e9rentiels, novembre 2021. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Evaluation-du-statut-MMR-tumoral-synthese-2021."},{"key":"10.1016\/j.dld.2024.01.208_bib0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2018.09.004","volume":"104","author":"Vangala","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2020.104080","article-title":"National recommendations of the French Genetics and Cancer Group - Unicancer on the modalities of multi-genes panel analyses in hereditary predispositions to tumors of the digestive tract","volume":"63","author":"Dhooge","year":"2020","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.dld.2024.01.208_bib0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","article-title":"Perioperative FOLFOX 4 versus FOLFOX4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase ii multicenter randomized controlled trial (PRODIGE 22)","volume":"271","author":"Karoui","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2024.01.208_bib0019","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(12)70348-0","article-title":"Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0020","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0034-1365307","article-title":"Place of colorectal stents in therapeutic management of malignant large bowel obstructions","volume":"46","year":"2014","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2024.01.208_bib0021","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0043-102569","article-title":"Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline","volume":"49","author":"Ferlitsch","year":"2017","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2024.01.208_bib0022","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1055\/a-1811-7025","article-title":"Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2022","volume":"54","author":"Pimentel-Nunes","year":"2022","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2024.01.208_bib0023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1055\/s-0034-1365348","article-title":"Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) guideline","volume":"46","author":"Kami\u0144ski","year":"2014","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2024.01.208_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1200\/JCO.2009.24.0952","article-title":"Revised TN categorization for colon cancer based on national survival outcomes data","volume":"28","author":"Gunderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0025","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.1999.17.5.1349","article-title":"Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)","volume":"17","author":"Mamounas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0026","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.1999.17.5.1356","article-title":"Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators","volume":"17","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2004.04.065","article-title":"Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials","volume":"22","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0028","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.1999.17.5.1356","article-title":"International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer","volume":"17","author":"Erlichman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0029","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2004.09.059","article-title":"Pooled analysis of fluorouracil- based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?","volume":"22","author":"Gill","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0030","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1200\/JCO.2004.03.087","article-title":"Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group","volume":"22","author":"Figueredo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0031","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","article-title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study","volume":"370","author":"Gray","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.01.208_bib0032","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0033","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","article-title":"Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses","volume":"29","author":"Yothers","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0034","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/cncr.30181","article-title":"Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer","volume":"122","author":"Casadaban","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0035","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","article-title":"Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study","volume":"33","author":"Andr\u00e9","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0036","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.20.01330","article-title":"Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer","volume":"39","author":"Iveson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0037","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1200\/JCO.2011.35.9539","article-title":"Isolated tumor cells in regional lymph nodes as relapse predictors in stage I and II colorectal cancer","volume":"30","author":"Mescoli C Mescoli","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0038","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0039","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0040","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdu499","article-title":"Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial","volume":"26","author":"Klingbiel","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0041","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jgo.2014.08.002","article-title":"High prevalence of deficient mismatch repair phenotype and the V600E BRAF mutation in elderly patients with colorectal cancer","volume":"5","author":"Aparicio","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0042","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ejca.2015.03.011","article-title":"Predictors of disease-free survival in colorectal cancer with microsatellite instability: an AGEO multicentre study","volume":"51","author":"Tougeron","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0043","doi-asserted-by":"crossref","first-page":"djv438","DOI":"10.1093\/jnci\/djv438","article-title":"Efficacy of adjuvant chemotherapy in colon cancer with microsatellite instability: a large multicenter AGEO study","volume":"108","author":"Tougeron","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2024.01.208_bib0044","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1200\/JCO.2010.33.0092","article-title":"Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer\u2013a study of CALGB 9581 and 89803","volume":"29","author":"Bertagnolli","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0045","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1200\/JCO.2010.32.8732","article-title":"Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer","volume":"29","author":"Gray","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0046","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1200\/JCO.2012.47.3116","article-title":"Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU\/LV) and FU\/LV plus oxaliplatin","volume":"31","author":"Yothers","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0047","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/jnci\/djs427","article-title":"Integrated analysis of molecular and clinical prognostic factors in stage II\/III colon cancer","volume":"104","author":"Roth","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2024.01.208_bib0048","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1200\/JCO.2012.45.1096","article-title":"Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581","volume":"31","author":"Venook","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0049","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1506597","article-title":"CDX2 as a prognostic biomarker in stage II and stage III colon cancer","volume":"374","author":"Dalerba","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0050","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.annonc.2020.03.310","article-title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study","volume":"31","author":"Pag\u00e8s","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0051","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.10526","article-title":"Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis","volume":"100","author":"Lecomte","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0052","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0053","article-title":"Prognostic value of circulating tumor DNA in patients with colon cancer: systematic review","volume":"12","author":"Fan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2024.01.208_bib0054","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","article-title":"Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma","volume":"322","author":"Moertel","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0056","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0016-5085(94)90748-X","article-title":"Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer","volume":"106","author":"Francini","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2024.01.208_bib0057","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)90696-7","article-title":"Efficacy of adjuvant fluorouracil and folinic acid in colon cancer","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.01.208_bib0058","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1200\/JCO.1997.15.1.246","article-title":"Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer","volume":"15","author":"O'Connell","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0059","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2135::AID-CNCR7>3.0.CO;2-U","article-title":"GIVIO-SITAC 01: a randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma \u2013 long term results and evaluation of the indicators of health-related quality of life","volume":"82","author":"Zaniboni","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0060","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(00)02214-5","article-title":"Comparison on fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2024.01.208_bib0061","doi-asserted-by":"crossref","first-page":"8671","DOI":"10.1200\/JCO.2004.00.5686","article-title":"Phase III study of fluorouracil, leucovorin, and levamisol in high-risk stage II and III colon cancer: final report of Intergroup 0089","volume":"23","author":"Haller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0062","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1200\/JCO.2007.12.2234","article-title":"Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1","volume":"25","author":"Andr\u00e9","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0063","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.ejca.2013.01.030","volume":"49","author":"K\u00f6hne","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0064","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","author":"Haller","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0066","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial","volume":"33","author":"Schmoll","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0067","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2015.63.0558","article-title":"Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database","volume":"34","author":"Shah","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0068","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0069","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2017.76.0355","article-title":"Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open\u2013label, International Duration Evaluation of Adjuvant (IDEA) France, phase III trial","volume":"36","author":"Andr\u00e9","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0070","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S1470-2045(18)30093-7","article-title":"3 versus 6 months of adjuvant oxaliplatinfluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non\u2013inferiority trial","volume":"19","author":"Iveson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0071","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1200\/JCO.2017.76.2187","article-title":"FOLFOX or CAPOX in stage II to III colon cancer: efficacy results of the Italian three or six colon adjuvant trial","volume":"36","author":"Sobrero","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0072","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2019.2572","article-title":"Efficacy and long-term peripheral sensory neuropathy of 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy for colon cancer: the ACHIEVE phase 3 randomized clinical trial","volume":"5","author":"Yoshino","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0073","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2020.10.477","article-title":"Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial","volume":"32","author":"Petrelli","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0074","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","article-title":"Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials","volume":"21","author":"Andr\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0075","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1200\/JCO.21.02726","article-title":"Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: an ACCENT\/IDEA pooled analysis of 11 adjuvant trials","volume":"41","author":"Gallois","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0076","first-page":"1","article-title":"Prognostic effec of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial","volume":"14","author":"Taieb","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0077","doi-asserted-by":"crossref","first-page":"djw272","DOI":"10.1093\/jnci\/djw272","article-title":"Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer","volume":"109","author":"Taieb","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.dld.2024.01.208_bib0078","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1158\/1078-0432.CCR-18-0866","article-title":"Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin based adjuvant chemotherapy","volume":"24","author":"Gallois","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2024.01.208_bib0079","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-21-0271","article-title":"Prognostic value and relation with adjuvant treatment duration of ctDNA in stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France trial","volume":"27","author":"Taieb","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2024.01.208_bib0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.annonc.2022.03.002","article-title":"Tumor budding is an independent prognostic factor in stage III colon cancer patients: a post-hoc analysis of the IDEA-France phase III trial (PRODIGE-GERCOR)","volume":"33","author":"Basile","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0081","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1200\/JCO.20.01600","article-title":"Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials","volume":"39","author":"Cohen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0082","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/annonc\/mdp383","article-title":"Impact of p53 expression and microsatellite instability on stage III colon cancer disease- free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin","volume":"21","author":"Zaanan","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0083","first-page":"e69","article-title":"Rationale and design of the IROCAS study: multicenter, international, randomized phase 3 trial comparing adjuvant modified (m) FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and\/or N2) colon cancer-a UNICANCER GI-PRODIGE trial","volume":"18","author":"Bennouna","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0084","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2007.11.2144","article-title":"Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803","volume":"25","author":"Saltz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0085","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/annonc\/mdn680","article-title":"A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02\/FFCD9802)","volume":"20","author":"Ychou","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0086","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2008.21.6663","article-title":"Randomized phase III trial comparing biweekly infusional fluorouracil\/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0087","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.ejca.2008.07.002","article-title":"Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomized phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)","volume":"44","author":"Popov","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0088","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2010.30.0855","article-title":"Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08","volume":"29","author":"Allegra","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0089","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","article-title":"Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial","volume":"13","author":"de Gramont","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0090","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S1470-2045(14)70227-X","article-title":"Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial","volume":"15","author":"Taieb","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0091","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.ejca.2015.08.016","article-title":"Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer","volume":"51","author":"Bos","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0092","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ejca.2010.01.020","article-title":"Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis","volume":"46","author":"Des Guetz","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0093","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jamcollsurg.2017.12.048","article-title":"Delay in adjuvant chemotherapy and survival advantage in stage III colon cancer","volume":"226","author":"Turner","year":"2018","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.dld.2024.01.208_bib0094","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0095","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1186\/s12885-022-09806-8","article-title":"Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial","volume":"22","author":"Kerckhove","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0096","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival","volume":"367","author":"Liao","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0097","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer","volume":"31","author":"Domingo","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0098","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clon.2015.11.008","article-title":"PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies","volume":"28","author":"Paleari","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0099","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12885-020-07117-4","article-title":"Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3109\/0284186X.2014.990158","article-title":"Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0101","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.dld.2017.12.023","article-title":"Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: a French randomised double-blind phase III trial (PRODIGE 50-ASPIK)","volume":"50","author":"Michel","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.01.208_bib0102","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1136\/gut.2005.068189","article-title":"Effect of physical activity and body size on survival after diagnosis with colorectal cancer","volume":"55","author":"Haydon","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.dld.2024.01.208_bib0103","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1200\/JCO.2006.06.0863","article-title":"Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803","volume":"24","author":"Meyerhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0104","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1200\/JCO.2006.06.0855","article-title":"Physical activity and survival after colorectal cancer diagnosis","volume":"24","author":"Meyerhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0105","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1200\/JCO.2014.59.7799","article-title":"Role of physical activity and diet after colorectal cancer diagnosis","volume":"33","author":"Van Blarigan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0106","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/annonc\/mdu012","article-title":"Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis","volume":"25","author":"Schmid","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0107","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1200\/JCO.19.02407","article-title":"Amount and intensity of leisure-time physical activity and lower cancer risk","volume":"38","author":"Matthews","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0108","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.01.208_bib0109","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0110","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0111","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1093\/annonc\/mdr366","article-title":"Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy","volume":"23","author":"Twelves","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0112","first-page":"250","article-title":"Feasibility of capecitabine and oxaliplatin combination chemotherapy without central venous access device in patients with stage III colorectal cancer","volume":"15","author":"Lapeyre-Prost","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.dld.2024.01.208_bib0113","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1093\/annonc\/mdr329","article-title":"Adjuvant capecitabine chemotherapy using a tailored dose strategy in elderly patients with colon cancer","volume":"23","author":"Chang","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0114","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa010957","article-title":"A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients","volume":"345","author":"Sargent","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2024.01.208_bib0115","first-page":"5587","article-title":"Stratified survival analysis after adjuvant chemotherapy of colon cancer reveals a benefit for older patients","volume":"35","author":"Mayer","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.dld.2024.01.208_bib0116","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2011.41.1140","article-title":"Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years","volume":"30","author":"Sanoff","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0117","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1200\/JCO.2013.49.6638","article-title":"Impact of age on the efficacy of newer adjuvant therapies in patients with stage II\/III colon cancer: findings from the ACCENT database","volume":"31","author":"McCleary","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0118","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdv003","article-title":"Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials","volume":"26","author":"Haller","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0119","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.dld.2015.11.023","article-title":"PRODIGE 34-FFCD 1402-ADAGE: adjuvant chemotherapy in elderly patients with resected stage III colon cancer: a randomized phase 3 trial","volume":"48","author":"Aparicio","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.01.208_bib0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40644-016-0104-2","article-title":"Assessment and diagnostic accuracy of lymph node status to predict stage III colon cancer using computed tomography","volume":"17","author":"Rollv\u00e9n","year":"2017","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.dld.2024.01.208_bib0121","doi-asserted-by":"crossref","first-page":"S3504","DOI":"10.1200\/JCO.2019.37.15_suppl.3504","article-title":"on behalf of the International FOxTROT Trial Investigators FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer","volume":"37","author":"Seymour","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0122","first-page":"S51389","article-title":"Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","volume":"33","author":"Chalabj","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0123","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0124","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.dld.2022.07.008","article-title":"Immunotherapy in MSI\/dMMR tumors in the perioperative setting: the IMHOTEP trial","volume":"54","author":"Coutzac","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2024.01.208_bib0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/bjs.5349","article-title":"Incidence and patterns of recurrence after resection for cure of colonic cancer in a well-defined population","volume":"93","author":"Manfredi","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.dld.2024.01.208_bib0126","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mdi151","article-title":"Time trends in the treatment and survival of recurrences from colorectal cancer","volume":"16","author":"Guyot","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0127","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1200\/JCO.2004.05.041","article-title":"The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0128","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2005.02.0826","article-title":"Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial","volume":"24","author":"Rodriguez-Moranta","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0129","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jama.2013.285718","article-title":"Effect of 3 to 5 years of scheduled CEA and CT followup to detect recurrence of colorectal cancer: the FACS randomized clinical trial","volume":"311","author":"Primrose","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.01.208_bib0130","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.2018.5623","article-title":"Effect of more vs less frequent follow up testing on overall and colorectal cancer- specific mortality in patients with stage II or III colorectal cancer: the COLOFOL randomized clinical trial","volume":"319","author":"Wille-Jorgensen","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2024.01.208_bib0131","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ejso.2015.06.008","article-title":"Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging: results of the randomized \"CEAwatch\" trial","volume":"41","author":"Verberne","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0132","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/annonc\/mdv541","article-title":"A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma","volume":"27","author":"Rosati","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0133","article-title":"Follow-up strategies for patients treated for non-metastatic colorectal cancer","volume":"9","author":"Jeffery","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.dld.2024.01.208_bib0134","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.024","article-title":"Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial","volume":"33","author":"Lepage","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2024.01.208_bib0135","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1007\/s10350-005-0096-7","article-title":"Patterns of surveillance practices after curative surgery for colorectal cancer in a French population","volume":"48","author":"Boulin","year":"2005","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.dld.2024.01.208_bib0136","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/a-0831-2522","article-title":"Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) guideline","volume":"51","author":"Hassan","year":"2019","journal-title":"Endoscopy"},{"key":"10.1016\/j.dld.2024.01.208_bib0137","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1055\/a-1185-3109","article-title":"Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2020","volume":"52","author":"Hassan","year":"2020","journal-title":"Endoscopy"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824002573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824002573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:23:38Z","timestamp":1761625418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824002573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":137,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1590865824002573"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.01.208","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-metastatic colon cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatments, and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, AFEF, and SFR)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.01.208","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}